Mutations in GUCY2D, the gene encoding retinal guanylate cyclase-1 (retGC1), are the leading cause of autosomal dominant cone–rod dystrophy (CORD6). Significant progress toward clinical application of gene replacement therapy for Leber congenital amaurosis (LCA) due to recessive mutations in GUCY2D (LCA1) has been made, but a different approach is needed to treat CORD6 where gain of function mutations cause dysfunction and dystrophy. The CRISPR/Cas9 gene editing system efficiently disrupts genes at desired loci, enabling complete gene knockout or homology directed repair. Here, adeno-associated virus (AAV)-delivered CRISPR/Cas9 was used specifically to edit/disrupt this gene's early coding sequence in mouse and macaque photoreceptors in vivo, thereby knocking out retGC1 expression and demonstrably altering retinal function and structure. Neither preexisting nor induced Cas9-specific T-cell responses resulted in ocular inflammation in macaques, nor did it limit GUCY2D editing. The results show, for the first time, the ability to perform somatic gene editing in primates using AAV-CRISPR/Cas9 and demonstrate the viability this approach for treating inherited retinal diseases in general and CORD6 in particular.
Get full access to this article
View all access options for this article.
References
1.
PayneAM, MorrisAG, DownesSM, et al.Clustering and frequency of mutations in the retinal guanylate cyclase (GUCY2D) gene in patients with dominant cone–rod dystrophies. J Med Genet, 2001; 38:611–614.
2.
MukherjeeR, RobsonAG, HolderGE, et al.A detailed phenotypic description of autosomal dominant cone dystrophy due to a de novo mutation in the GUCY2D gene. Eye (Lond), 2014; 28:481–487.
3.
Gregory-EvansK, KelsellRE, Gregory-EvansCY, et al.Autosomal dominant cone–rod retinal dystrophy (CORD6) from heterozygous mutation of GUCY2D, which encodes retinal guanylate cyclase. Ophthalmology, 2000; 107:55–61.
4.
MooreAT. Cone and cone–rod dystrophies. J Med Genet, 1992; 29:289–290.
5.
DizhoorAM, LoweDG, OlshevskayaEV, et al.The human photoreceptor membrane guanylyl cyclase, RetGC, is present in outer segments and is regulated by calcium and a soluble activator. Neuron, 1994; 12:1345–1352.
6.
LiuX, SenoK, NishizawaY, et al.Ultrastructural localization of retinal guanylate cyclase in human and monkey retinas. Exp Eye Res, 1994; 59:761–768.
7.
OlshevskayaEV, PeshenkoIV, SavchenkoAB, et al.Retinal guanylyl cyclase isozyme 1 is the preferential in vivo target for constitutively active GCAP1 mutants causing congenital degeneration of photoreceptors. J Neurosci, 2012; 32:7208–7217.
8.
BurnsME, ArshavskyVY. Beyond counting photons: trials and trends in vertebrate visual transduction. Neuron, 2005; 48:387–401.
9.
KaranS, FrederickJM, BaehrW. Novel functions of photoreceptor guanylate cyclases revealed by targeted deletion. Mol Cell Biochem, 2010; 334:141–155.
10.
PerraultI, RozetJM, CalvasP, et al.Retinal-specific guanylate cyclase gene mutations in Leber's congenital amaurosis. Nat Genet, 1996; 14:461–464.
11.
PerraultI, RozetJM, GerberS, et al.Spectrum of retGC1 mutations in Leber's congenital amaurosis. Eur J Hum Genet, 2000; 8:578–582.
12.
KelsellRE, Gregory-EvansK, PayneAM, et al.Mutations in the retinal guanylate cyclase (RETGC-1) gene in dominant cone–rod dystrophy. Hum Mol Genet, 1998; 7:1179–1184.
13.
PerraultI, RozetJM, GerberS, et al.A retGC-1 mutation in autosomal dominant cone–rod dystrophy. Am J Hum Genet, 1998; 63:651–654.
14.
TuckerCL, WoodcockSC, KelsellRE, et al.Biochemical analysis of a dimerization domain mutation in RetGC-1 associated with dominant cone–rod dystrophy. Proc Natl Acad Sci U S A, 1999; 96:9039–9044.
15.
WilkieSE, NewboldRJ, DeeryE, et al.Functional characterization of missense mutations at codon 838 in retinal guanylate cyclase correlates with disease severity in patients with autosomal dominant cone–rod dystrophy. Hum Mol Genet, 2000; 9:3065–3073.
16.
DizhoorAM, OlshevskayaEV, PeshenkoIV. The R838S mutation in retinal guanylyl cyclase 1 (RetGC1) alters calcium sensitivity of cGMP synthesis in the retina and causes blindness in transgenic mice. J Biol Chem, 2016; 291:24504–24516.
17.
SatoS, PeshenkoIV, OlshevskayaEV, et al.GUCY2D cone–rod dystrophy-6 is a “phototransduction disease” triggered by abnormal calcium feedback on retinal membrane guanylyl cyclase 1. J Neurosci, 2018; 38:2990–3000.
18.
GreenDR, ReedJC. Mitochondria and apoptosis. Science, 1998; 281:1309–1312.
19.
BoyeSE, BoyeSL, PangJ, et al.Functional and behavioral restoration of vision by gene therapy in the guanylate cyclase-1 (GC1) knockout mouse. PLoS One, 2010; 5:e11306.
20.
BoyeSL, ConlonT, ErgerK, et al.Long-term preservation of cone photoreceptors and restoration of cone function by gene therapy in the guanylate cyclase-1 knockout (GC1KO) mouse. Invest Ophthalmol Vis Sci, 2011; 52:7098–7108.
21.
BoyeSL, PeshenkoIV, HuangWC, et al.AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis. Hum Gene Ther, 2013; 24:189–202.
22.
JacobsonSG, CideciyanAV, PeshenkoIV, et al.Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants. Hum Mol Genet, 2013; 22:168–183.
23.
HsuPD, LanderES, ZhangF. Development and applications of CRISPR-Cas9 for genome engineering. Cell, 2014; 157:1262–1278.
24.
SanderJD, JoungJK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol, 2014; 32:347–355.
25.
DoudnaJA, CharpentierE. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science, 2014; 346:1258096.
26.
YinH, XueW, ChenS, et al.Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol, 2014; 32:551–553.
27.
OusteroutDG, KabadiAM, ThakorePI, et al.Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun, 2015; 6:6244.
28.
TabebordbarM, ZhuK, ChengJKW, et al.In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science, 2016; 351:407–411.
29.
YuW, MookherjeeS, ChaitankarV, et al.Nrl knockdown by AAV-delivered CRISPR/Cas9 prevents retinal degeneration in mice. Nat Commun, 2017; 8:14716.
30.
RuanGX, BarryE, YuD, et al.CRISPR/Cas9-mediated genome editing as a therapeutic approach for Leber congenital amaurosis 10. Mol Ther, 2017; 25:331–341.
31.
KooT, ParkSW, JoDH, et al.CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration. Nat Commun, 2018; 9:1855.
32.
BoyeSE, BoyeSL, LewinAS, et al.A comprehensive review of retinal gene therapy. Mol Ther, 2013; 21:509–519.
33.
JacobsonSG, BoyeSL, AlemanTS, et al.Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Hum Gene Ther, 2006; 17:845–858.
34.
MaclachlanTK, LukasonM, CollinsM, et al.Preclinical safety evaluation of AAV2-sF. Mol Ther, 2011; 19:326–334.
35.
YeGJ, BudzynskiE, SonnentagP, et al.Cone-specific promoters for gene therapy of achromatopsia and other retinal diseases. Hum Gene Ther, 2016; 27:72–82.
36.
BoyeSE, AlexanderJJ, BoyeSL, et al.The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina. Hum Gene Ther, 2012; 23:1101–1115.
37.
BeltranWA, CideciyanAV, BoyeSE, et al.Optimization of retinal gene therapy for X-linked retinitis pigmentosa due to RPGR mutations. Mol Ther, 2017; 25:1866–1880.
38.
BakondiB, LvW, LuB, et al.In vivo CRISPR/Cas9 gene editing corrects retinal dystrophy in the S334ter-3 rat model of autosomal dominant retinitis pigmentosa. Mol Ther, 2016; 24:556–563.
39.
HungSS, ChrysostomouV, LiF, et al.AAV-mediated CRISPR/Cas gene editing of retinal cells in vivo. Invest Ophthalmol Vis Sci, 2016; 57:3470–3476.
40.
BaeS, ParkJ, KimJS. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics, 2014; 30:1473–1475.
41.
YangRB, RobinsonSW, XiongWH, et al.Disruption of a retinal guanylyl cyclase gene leads to cone-specific dystrophy and paradoxical rod behavior. J Neurosci, 1999; 19:5889–5897.
42.
ShenS, SanchezME, BlomenkampK, et al.Amelioration of alpha-1 antitrypsin deficiency diseases with genome editing in transgenic mice. Hum Gene Ther, 2018; 29:861–873.
43.
FriedlandAE, BaralR, SinghalP, et al.Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications. Genome Biol, 2015; 16:257.
44.
ZolotukhinS. Production of recombinant adeno-associated virus vectors. Hum Gene Ther, 2005; 16:551–557.
45.
TimmersAM, ZhangH, SquitieriA, et al.Subretinal injections in rodent eyes: effects on electrophysiology and histology of rat retina. Mol Vis, 2001; 7:131–137.
46.
ChoudhuryS, StrangCE, AlexanderJJ, et al.Novel methodology for creating macaque retinas with sortable photoreceptors and ganglion cells. Front Neurosci, 2016; 10:551.
47.
PangJJ, DaiX, BoyeSE, et al.Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa. Mol Ther, 2011; 19:234–242.
48.
BoyeSE, AlexanderJJ, WitherspoonCD, et al.Highly efficient delivery of adeno-associated viral vectors to the primate retina. Hum Gene Ther, 2016; 27:580–597.
49.
KayCN, RyalsRC, AslanidiGV, et al.Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors. PLoS One, 2013; 8:e62097.
50.
GiannoukosG, CiullaDM, MarcoE, et al.UDiTaS, a genome editing detection method for indels and genome rearrangements. BMC Genomics, 2018; 19:212.
51.
MoodieZ, PriceL, GouttefangeasC, et al.Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother, 2010; 59:1489–1501.
52.
KhaniSC, PawlykBS, BulgakovOV, et al.AAV-mediated expression targeting of rod and cone photoreceptors with a human rhodopsin kinase promoter. Invest Ophthalmol Vis Sci, 2007; 48:3954–3961.
53.
StaurenghiG, SaddaS, ChakravarthyU, et al.Proposed lexicon for anatomic landmarks in normal posterior segment spectral-domain optical coherence tomography: the IN*OCT consensus. Ophthalmology, 2014; 121:1572–1578.
54.
JarrettKE, LeeCM, YehYH, et al.Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease. Sci Rep, 2017; 7:44624.
55.
InagakiK, MaC, StormTA, et al.The role of DNA-PKcs and artemis in opening viral DNA hairpin termini in various tissues in mice. J Virol, 2007; 81:11304–11321.
56.
YoungSMJr, SamulskiRJ. Adeno-associated virus (AAV) site-specific recombination does not require a Rep-dependent origin of replication within the AAV terminal repeat. Proc Natl Acad Sci U S A, 2001; 98:13525–13530.
57.
NaultJC, DattaS, ImbeaudS, et al.Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet, 2015; 47:1187–1193.
58.
BernsKI, ByrneBJ, FlotteTR, et al.Adeno-associated virus type 2 and hepatocellular carcinoma?. Hum Gene Ther, 2015; 26:779–781.
59.
Gil-FarinaI, FronzaR, KaeppelC, et al.Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients. Mol Ther, 2016; 24:1100–1105.
60.
SimhadriVL, McGillJ, McMahonS, et al.Prevalence of pre-existing antibodies to CRISPR-associated nuclease Cas9 in the USA population. Mol Ther Methods Clin Dev, 2018; 10:105–112.
61.
MilamAH, BarakatMR, GuptaN, et al.Clinicopathologic effects of mutant GUCY2D in Leber congenital amaurosis. Ophthalmology, 2003; 110:549–558.
62.
PortoFB, PerraultI, HicksD, et al.Prenatal human ocular degeneration occurs in Leber's congenital amaurosis (LCA1 and 2). Adv Exp Med Biol, 2003; 533:59–68.
63.
SimonelliF, ZivielloC, TestaF, et al.Clinical and molecular genetics of Leber's congenital amaurosis: a multicenter study of Italian patients. Invest Ophthalmol Vis Sci, 2007; 48:4284–4290.
64.
PasadhikaS, FishmanGA, StoneEM, et al.Differential macular morphology in patients with RPE65-, CEP290-, GUCY2D-, and AIPL1-related Leber congenital amaurosis. Invest Ophthalmol Vis Sci, 2010; 51:2608–2614.
65.
BoyeSE. Gene therapy fully restores vision to the all-cone Nrl(–/–) Gucy2e(–/–) mouse model of Leber congenital amaurosis-1. Hum Mol Genet, 2015; 26:575–592.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
